Search

Anne Marie Sabrina Wehbe

Examiner (ID: 18312)

Most Active Art Unit
1633
Art Unit(s)
1632, 1633, 1634
Total Applications
1342
Issued Applications
603
Pending Applications
239
Abandoned Applications
542

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 16266465 [patent_doc_number] => 20200267952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => TRANSGENIC NON-HUMAN VERTEBRATE FOR THE IN VIVO PRODUCTION OF DUAL SPECIFICITY IMMUNOGLOBULINS OR HYPERMUTATED HEAVY CHAIN ONLY IMMUNOGLOBULINS [patent_app_type] => utility [patent_app_number] => 16/869416 [patent_app_country] => US [patent_app_date] => 2020-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16869416 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/869416
TRANSGENIC NON-HUMAN VERTEBRATE FOR THE IN VIVO PRODUCTION OF DUAL SPECIFICITY IMMUNOGLOBULINS OR HYPERMUTATED HEAVY CHAIN ONLY IMMUNOGLOBULINS May 6, 2020 Pending
Array ( [id] => 17670963 [patent_doc_number] => 20220184130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => ARTIFICIAL SIGNALLING MOLECULE [patent_app_type] => utility [patent_app_number] => 17/605180 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5993 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605180 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/605180
ARTIFICIAL SIGNALLING MOLECULE Apr 29, 2020 Pending
Array ( [id] => 17670963 [patent_doc_number] => 20220184130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => ARTIFICIAL SIGNALLING MOLECULE [patent_app_type] => utility [patent_app_number] => 17/605180 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5993 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605180 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/605180
ARTIFICIAL SIGNALLING MOLECULE Apr 29, 2020 Pending
Array ( [id] => 16510818 [patent_doc_number] => 20200390074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => Non-Mammalian RAS Transgenic Animal Model [patent_app_type] => utility [patent_app_number] => 16/854118 [patent_app_country] => US [patent_app_date] => 2020-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16854118 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/854118
Non-Mammalian RAS Transgenic Animal Model Apr 20, 2020 Abandoned
Array ( [id] => 16283769 [patent_doc_number] => 20200277371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => Restricted Immunoglobulin Heavy Chain Mice [patent_app_type] => utility [patent_app_number] => 16/851902 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28427 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851902 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/851902
Restricted Immunoglobulin Heavy Chain Mice Apr 16, 2020 Abandoned
Array ( [id] => 16204835 [patent_doc_number] => 20200237825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => ENGINEERING AND DELIVERY OF THERAPEUTIC COMPOSITIONS OF FRESHLY ISOLATED CELLS [patent_app_type] => utility [patent_app_number] => 16/849954 [patent_app_country] => US [patent_app_date] => 2020-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14043 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16849954 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/849954
ENGINEERING AND DELIVERY OF THERAPEUTIC COMPOSITIONS OF FRESHLY ISOLATED CELLS Apr 14, 2020 Abandoned
Array ( [id] => 16295452 [patent_doc_number] => 20200281175 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => HUMANIZED NON-HUMAN ANIMALS WITH RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN LOCI [patent_app_type] => utility [patent_app_number] => 16/849782 [patent_app_country] => US [patent_app_date] => 2020-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49514 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16849782 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/849782
Humanized non-human animals with restricted immunoglobulin heavy chain loci Apr 14, 2020 Issued
Array ( [id] => 16388743 [patent_doc_number] => 20200329684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => METHOD FOR OBTAINING RETINAL DEGENERATION (rd) MODEL MOUSE HAVING LOW RISK OF CAUSING RETINAL DETACHMENT [patent_app_type] => utility [patent_app_number] => 16/846718 [patent_app_country] => US [patent_app_date] => 2020-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3153 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16846718 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/846718
METHOD FOR OBTAINING RETINAL DEGENERATION (rd) MODEL MOUSE HAVING LOW RISK OF CAUSING RETINAL DETACHMENT Apr 12, 2020 Abandoned
Array ( [id] => 20386610 [patent_doc_number] => 12486327 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => CAR for use in the treatment of HvG disease [patent_app_type] => utility [patent_app_number] => 17/442759 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 2843 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17442759 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/442759
CAR for use in the treatment of HvG disease Mar 29, 2020 Issued
Array ( [id] => 20386610 [patent_doc_number] => 12486327 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => CAR for use in the treatment of HvG disease [patent_app_type] => utility [patent_app_number] => 17/442759 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 2843 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17442759 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/442759
CAR for use in the treatment of HvG disease Mar 29, 2020 Issued
Array ( [id] => 16397273 [patent_doc_number] => 20200338131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => Method [patent_app_type] => utility [patent_app_number] => 16/827708 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19382 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16827708 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/827708
Method Mar 23, 2020 Abandoned
Array ( [id] => 17609888 [patent_doc_number] => 20220152167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => IMMUNOGENIC FORMULATIONS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/436380 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10715 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -77 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17436380 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/436380
IMMUNOGENIC FORMULATIONS FOR TREATING CANCER Mar 4, 2020 Pending
Array ( [id] => 19104692 [patent_doc_number] => 11957765 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Gene therapy for neurometabolic disorders [patent_app_type] => utility [patent_app_number] => 16/808206 [patent_app_country] => US [patent_app_date] => 2020-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 37 [patent_no_of_words] => 13659 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16808206 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/808206
Gene therapy for neurometabolic disorders Mar 2, 2020 Issued
Array ( [id] => 16072463 [patent_doc_number] => 20200190218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => ENHANCED PRODUCTION OF IMMUNOGLOBULINS [patent_app_type] => utility [patent_app_number] => 16/802978 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12502 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16802978 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/802978
ENHANCED PRODUCTION OF IMMUNOGLOBULINS Feb 26, 2020 Abandoned
Array ( [id] => 16108501 [patent_doc_number] => 20200206273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => METHOD FOR CHEMOSELECTION [patent_app_type] => utility [patent_app_number] => 16/798108 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10430 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798108 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/798108
Method for chemoselection Feb 20, 2020 Issued
Array ( [id] => 16266463 [patent_doc_number] => 20200267950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => RODENTS HAVING GENETICALLY MODIFIED SODIUM CHANNELS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/797280 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31250 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16797280 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/797280
Rodents having genetically modified sodium channels and methods of use thereof Feb 20, 2020 Issued
Array ( [id] => 15863043 [patent_doc_number] => 20200138925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => PROSTATE CANCER VACCINE [patent_app_type] => utility [patent_app_number] => 16/745629 [patent_app_country] => US [patent_app_date] => 2020-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16745629 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/745629
PROSTATE CANCER VACCINE Jan 16, 2020 Abandoned
Array ( [id] => 16188560 [patent_doc_number] => 20200229409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => RODENT MODEL OF MOOD DISORDERS [patent_app_type] => utility [patent_app_number] => 16/744493 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16744493 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/744493
Rodent model of mood disorders Jan 15, 2020 Issued
Array ( [id] => 16220484 [patent_doc_number] => 20200245600 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => In Vivo Method for Generating Diversity in a Protein Scaffold [patent_app_type] => utility [patent_app_number] => 16/735468 [patent_app_country] => US [patent_app_date] => 2020-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8702 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16735468 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/735468
In vivo method for generating diversity in a protein scaffold Jan 5, 2020 Issued
Array ( [id] => 17074901 [patent_doc_number] => 11111286 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-07 [patent_title] => T cell receptors and immune therapy using the same against PRAME positive cancers [patent_app_type] => utility [patent_app_number] => 16/731139 [patent_app_country] => US [patent_app_date] => 2019-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 21503 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 319 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16731139 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/731139
T cell receptors and immune therapy using the same against PRAME positive cancers Dec 30, 2019 Issued
Menu